DCGI approves Covishield and Covaxin for emergency use in India

Credit:  Artem Podrez from Pexels

The DCGI has approved two COVID-19 vaccines for restricted emergency use approval (EUA) in India.  Covaxin from Bharat Biotech, and Covishield which will be manufactured from Serum Institute of India, have received the approval from India’s drug regulator.

Bharat Biotech’s Covaxin is an indigenous vaccine being developed in collaboration with the Indian Council of Medical Research (ICMR). Covishield is a COVID-19 vaccine developed by AstraZeneca and Oxford University.

Dr VG Somani, Drugs Controller General of India announced the approval of these vaccines through a press conference today. DCGI’s decision comes after the Subject Expert Committee of CDSCO met on January 1-2, 2021 and recommended the grant of permission for restricted emergency use of these vaccines, subject to multiple regulatory conditions.

This paves the way for COVID-19 vaccine administration in India, offering a major turning point against the pandemic.

India's regulator has also received an emergency-use application for the Covid-19 vaccine made by Pfizer Inc with Germany's BioNTech - the first shot to secure regulatory approval in the West.

Current Issue

NEWSLETTER